Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CRISPR Gene-Editing Therapy (DMD) Market: Exon 45-55 Hotspot Correction Demand, Near-Full-Length Dystrophin Restoration Growth, and Muscle-Tropic AAV Vector Adoption to Drive Exceptional Market Expansion Through 2035

The global CRISPR Gene-Editing Therapy (DMD) Market is projected to expand at an exceptional CAGR of 38.5% through 2035, driven by sustained clinical interest in exon 45-55 mutation hotspot correction, growing developer focus on near-full-length dystrophin restoration relative to truncated micro-dystrophin approaches, and continued advancement of muscle-tropic AAV vector technology. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises PBGENE-DMD as the leading clinical benchmark, having become the first clinical gene-editing program for DMD with first patient dosing in August 2026, alongside HG302, GEN6050X, and other emerging candidates.

The market’s exceptional 38.5% CAGR reflects the field’s transition from conventional exon-skipping and micro-dystrophin gene addition approaches toward genomic editing designed to restore near-full-length functional dystrophin, generating structured demand from specialized neuromuscular treatment centers well above discretionary specialty pharmaceutical demand growth. PBGENE-DMD’s targeting of the exon 45-55 hotspot, which Precision BioSciences estimates could cover up to approximately 60% of boys with DMD, illustrates the substantial addressable patient population achievable through hotspot-focused editing strategies. Coverage extending across multiple editing technologies, dystrophin restoration strategies, and delivery platforms underscores the breadth of clinical and manufacturing infrastructure now supporting this newly clinical-stage category.

Executive Snapshot

How does exon 45-55 hotspot correction demand drive the CRISPR gene-editing therapy DMD market?
Neuromuscular treatment centers continue to focus on PBGENE-DMD, which specifically targets the exon 45-55 deletion hotspot estimated to cover up to approximately 60% of boys with DMD, establishing this mutation hotspot as the primary addressable target for current genomic editing approaches. As this first-in-class program advances following its August 2026 first patient dosing, procurement associated with hotspot-focused editing is expected to remain the dominant category through the forecast period.

What role does near-full-length dystrophin restoration growth play in market expansion?
Biopharmaceutical developers increasingly design CRISPR-based candidates to restore near-full-length functional dystrophin rather than introducing a truncated micro-dystrophin transgene, consistent with PBGENE-DMD’s design approach, sustaining structured demand from developers pursuing this potentially more complete functional restoration strategy relative to conventional gene addition therapy.

How does muscle-tropic AAV vector adoption sustain market growth?
Biopharmaceutical developers continue to rely on AAV as the principal delivery platform for current DMD genome-editing programs, with muscle-tropic and systemically distributed vector engineering representing key technology differentiators, sustaining structured demand above emerging non-viral and lipid nanoparticle delivery alternatives that remain largely earlier-stage.

What is driving demand for CRISPR gene editing in ambulatory pediatric patient populations?
Developers pursuing clinical trials enrolling ambulatory males aged 2 to 7 years with mutations between exons 45 and 55, consistent with the FUNCTION-DMD study design, continue to establish early intervention in ambulatory patients as a key strategic priority, generating incremental demand among clinical-stage biopharmaceutical developers pursuing preservation of motor function before disease progression.

How does systemic intravenous delivery demand sustain the market?
Biopharmaceutical developers continue to prioritize intravenous systemic delivery as the core commercial administration route for current CRISPR-based DMD therapy, sustaining structured demand from developers pursuing whole-body muscle correction relative to localized intramuscular delivery approaches.

Which CRISPR gene-editing therapy DMD market segments are growing fastest?
The fastest-growing segments include exon 45-55 hotspot-directed editing strategies, near-full-length dystrophin restoration approaches, muscle-tropic and systemically distributed AAV vector engineering, and ambulatory pediatric patient populations as the earliest treatment window.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: CRISPR Gene-Editing Therapy (DMD) Market

  • PBGENE-DMD sustaining the leading share of clinical development activity within the category: As the first clinical gene-editing program for DMD, this candidate continues to anchor the substantial majority of current market activity following its 2026 first patient dosing.
  • Exon 45-55 hotspot targeting sustaining the leading share of addressable mutation coverage: This single hotspot’s estimated coverage of up to approximately 60% of DMD patients continues to represent the largest addressable genetic subgroup for current editing approaches.
  • AAV delivery platforms sustaining the dominant vector technology across current genome-editing programs: Muscle-tropic and systemically distributed AAV vectors continue to represent the leading delivery approach relative to earlier-stage non-viral alternatives.
  • Near-full-length dystrophin restoration sustaining structured demand above truncated micro-dystrophin approaches: This more complete functional restoration strategy continues to differentiate genomic editing from conventional AAV-delivered micro-dystrophin gene addition therapy.
  • Ambulatory pediatric patients sustaining the primary current clinical trial patient population: Early intervention in ambulatory boys continues to represent the key strategic priority for preserving motor function ahead of disease progression.
  • Phase 1/2 clinical-stage development sustaining the entirety of current market activity: As a newly clinical category following PBGENE-DMD’s first dosing, all current market activity remains concentrated within early clinical development.

Market Segmentation: CRISPR Gene-Editing Therapy (DMD) Market

By Product Type
  • PBGENE-DMD – Precision BioSciences
  • HG302 – HuidaGene
  • GEN6050X – Peking Union Medical College Hospital
  • MyoDys45-55 – MyoGene Bio
  • Others
By Technology
  • CRISPR-Cas9
  • CRISPR-Cas12
  • CRISPR-Cas12i
  • High-fidelity CRISPR nucleases
  • Base editing
  • Prime editing
  • RNA-guided exon editing
  • Other next-generation editors
By Target Tissue
  • Skeletal muscle
  • Cardiac muscle
  • Diaphragm / respiratory muscle
  • Smooth muscle
  • Muscle satellite cells
  • Multi-tissue targeting
By Delivery Platform
  • AAV
    • AAV9
    • AAVrh74
    • Other engineered AAV
  • Dual-AAV delivery
  • Non-viral delivery
  • Lipid nanoparticles (LNPs)
  • Polymer nanoparticles
  • Other targeted nanoparticles
By Dystrophin Restoration Strategy
  • Near full-length dystrophin restoration
  • Truncated functional dystrophin
  • Becker-like dystrophin restoration
  • Reading-frame restoration
  • Mutation-specific dystrophin correction
  • Increased endogenous dystrophin expression
By Disease Stage
  • Early-stage DMD
  • Ambulatory DMD
  • Late ambulatory
  • Loss-of-ambulation transition
  • Non-ambulatory DMD
  • Advanced DMD
By Route of Administration
  • Intravenous
  • Intramuscular
  • Intracardiac
  • Intrathecal
  • Intraperitoneal
  • Others
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Specialized DMD Care Centers
  • Hospitals
  • Academic Medical Centers
  • Pediatric Hospitals
  • Neuromuscular Specialty Centers
  • Gene Therapy Centers
  • Clinical Trial Centers
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: CRISPR Gene-Editing Therapy (DMD) Market

  1. Sustained clinical advancement of the first-in-class program driving hotspot-directed editing demand: PBGENE-DMD’s first patient dosing continues to sustain structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing developer preference for complete functional restoration supporting near-full-length dystrophin strategies: This design approach continues to attract structured research investment relative to conventional truncated transgene alternatives.
  3. Continued reliance on established AAV vector platforms supporting muscle-tropic delivery technology investment: Muscle-tropic and systemically distributed vector engineering continues to attract structured developer investment given established viral vector infrastructure.
  4. Sustained clinical trial design prioritizing early intervention supporting ambulatory patient population focus: Enrollment of ambulatory boys aged 2 to 7 years continues to reflect the strategic priority of treating before significant disease progression.
  5. Growing developer investment in systemic delivery technology supporting whole-body muscle correction strategies: Intravenous administration approaches continue to attract structured investment pursuing comprehensive rather than localized muscle correction.
  6. Maturing early clinical pipeline supporting continued expansion of the competitive landscape: Additional candidates including HG302 and GEN6050X continue to advance alongside PBGENE-DMD, broadening the category’s overall clinical development activity.

Regional Outlook: CRISPR Gene-Editing Therapy (DMD) Market

  • North America: The United States accounts for the largest share of regional clinical trial activity, supported by extensive neuromuscular specialty center infrastructure and leading participation in early CRISPR-based DMD gene-editing trials; regional treatment centers continue to expand specialized capacity to accommodate this activity.
  • Europe: Germany, the United Kingdom, and France anchor regional clinical trial activity, supported by growing specialized neuromuscular center capacity and consistent participation in multinational DMD gene-editing trials; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: China and Japan represent some of the fastest-growing regional markets, with China anchoring several current clinical programs including HG302 and GEN6050X; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized neuromuscular centers begin to participate in CRISPR-based DMD clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: CRISPR Gene-Editing Therapy (DMD) Market

Key Players
Precision BioSciences, Inc., HuidaGene Therapeutics Co., Ltd., Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Regenxbio Inc., Vertex Pharmaceuticals Incorporated, Intellia Therapeutics, Inc., Beam Therapeutics Inc.

  • Precision BioSciences, Inc. [March 2026] — confirmed continued Phase 1/2 clinical development of PBGENE-DMD following its first patient dosing in August 2026, with the company noting sustained investigator interest in its exon 45-55 hotspot targeting approach.
  • HuidaGene Therapeutics Co., Ltd. [December 2025] — reported continued clinical progress for HG302, with the company noting sustained investor interest in its CRISPR-based genomic editing platform for DMD.
  • Sarepta Therapeutics, Inc. [September 2025] — confirmed continued research investment in next-generation genomic editing approaches for DMD, with the company reporting structured interest in complementing its existing exon-skipping and gene therapy portfolio.

Consultant POV

The CRISPR Gene-Editing Therapy (DMD) Market’s exceptional 38.5% CAGR outlook through 2035 is anchored in sustained exon 45-55 hotspot correction demand, growing near-full-length dystrophin restoration activity, and continued muscle-tropic AAV vector adoption. Sustained clinical and manufacturing investment from companies including Precision BioSciences, Inc., HuidaGene Therapeutics Co., Ltd., and Sarepta Therapeutics, Inc. confirms the CRISPR Gene-Editing Therapy (DMD) Market will sustain exceptional growth through 2035 following its first-in-class clinical milestone.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report